Press Releases
Biopharma PEG Announces Key Product Line of Monodispersed PEGs for Advanced Pharmaceutical Applications
Watertown, MA, July 22, 2024 – Biopharma PEG, a leading supplier of high-quality polyethylene glycol (PEG) derivatives, is excited to highlight its important product line of monodispersed PEGs. These products are critical for applications in Antibody-Drug Conjugate (ADC) linkers, Proteolysis Targeting Chimeras (PROTAC) linkers, and PEGylated proteins and peptides, offering significant advancements in drug stability and delivery.
Monodispersed PEGs are precisely sized polymers that enhance the stability and delivery of proteins and peptides in pharmaceuticals. Their uniform molecular weight distribution ensures consistent performance, making them indispensable in various therapeutic applications.
Monodispersed PEGs as ADC Linkers
The use of PEGs as linkers between antibody and payload molecules allows for higher ADC loading. PEGs create a protective shield that wraps the ADC payload from its microenvironment, improving solubility and stability. Additional benefits include reduced aggregation and lower immunogenicity, improved pharmacokinetics, increased circulation time, and reduced toxicity.
Key products include:
mPEG36-NH2 (CAS NO.: 32130-27-1)
OH-PEG6-COOH (CAS NO.: 1347750-85-9)
CBZ-NH-PEG3-COOH (CAS NO.: 1310327-18-4)
OH-PEG9-OH (CAS NO.: 3386-18-3)
Monodispersed PEGs as PROTAC Linkers
Several kinds of linkers have been reported and applied in PROTAC ternary complexes formation, with PEG linkers being the most common motifs. According to statistics, 54% of reported PROTAC molecules use PEG as a linker. The introduction of PEG can increase the water solubility of PROTAC molecules and affect cell permeability, thereby influencing oral absorption. Systematic changes in linker length can be easily achieved by using PEGs of different chain lengths, impacting the degradation efficiency of PROTAC molecules. The use of various bifunctionalized PEG linkers enables simple and rapid assembly of molecules with different linker groups, accelerating the screening of efficient degradation structures.
Key products include:
Fmoc-NH-PEG12-COOH (CAS NO.: 756526-01-9)
NH2-PEG4-OH (CAS NO.: 86770-74-3)
N3-PEG3-SPA (CAS NO.: 1245718-89-1)
N3-PEG6-OH (CAS NO.: 86770-69-6)
PEGylated Protein & Peptide
PEGylation improves the pharmacokinetics of molecules by reducing clearance and increasing half-life, increasing the dosing interval, and improving patient convenience compared to non-PEGylated products. Additionally, PEGylation of therapeutic agents is valuable in reducing immunogenicity, antigenicity, and toxicity, as well as significantly reducing renal clearance of the drug while maintaining drug efficacy.
Key products include:
N3-PEG11-NH2 (CAS NO.: 1800414-71-4)
NH2-PEG24-COOH (CAS NO.: 196936-04-6)
mPEG11-COOH (CAS NO.: 2135793-73-4)
mPEG6-OH (CAS NO.: 23601-40-3)
"We can provide lab to commercial scale monodispersed PEG linkers in both GMP and non-GMP grades," said Sonia Lee, marketing director of Biopharma PEG. "Our monodispersed PEGs are engineered to meet the highest standards of quality and performance, supporting the development of advanced pharmaceuticals."
For more information about Biopharma PEG and their monodispersed PEG products, please visit www.biochempeg.com or contact us at sales@biochempeg.com.
Media Contact:
Biopharma PEG
108 Water Street, Suite 4D, Watertown, MA 02472, USA
TEL: 1-857-928-2050 / 1-857-366-6766
About Biopharma PEG:
Biopharma PEG is a leading supplier of PEG derivatives, dedicated to supporting the pharmaceutical, biotechnology, and medical device industries with high-quality products that enhance the performance and delivery of therapeutic agents. For more information, visit www.biochempeg.com.
